InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Discover the detailed record of transactions filed by ZANTE GREG, Chief Financial Officer. Officer active across 1 companies, notably Viking Therapeutics, Inc.. Cumulatively, 4 filings have been published. The latest transaction was filed on 3 January 2022 (Retenue fiscale). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations4 total
€13,2883,097 shares@ €4.2907100.0% of flow
Common Stock, par value $0.00001 per share
SEC:0001209191-22-001988·
€13,2883,097 shares@ €4.29070.0004% mcap50.0% of flow
Common Stock, par value $0.00001 per share
SEC:0001209191-22-001988:0·
06,667 shares0
Common Stock, par value $0.00001 per share
SEC:0001209191-21-058246·
06,667 shares0
Common Stock, par value $0.00001 per share
SEC:0001209191-21-058246:0·
4 of 4 declarations
About ZANTE GREG
Greg Zante is the Chief Financial Officer of Viking Therapeutics, Inc. In this role, he oversees the company's financial operations, including financial planning and reporting. With a strong background in finance, he plays a key role in managing financial resources and regulatory compliance. His expertise is essential in ensuring the financial health of Viking Therapeutics and supporting its mission of innovation.
